Rationale: Primary cutaneous anaplastic large-cell lymphoma (C-ALCL) is a rare cancer belonging to the group of primary T-cell lymphoproliferative diseases. C-ALCL is characterized by the presence of single or multiple ulcerated lesions on the skin's surface.
Introduction
The most common nonmelanoma skin cancer of the face is basal cell carcinoma, which accounts for 80% of all skin lesions, followed by squamous cell carcinoma. [1] The prevalence of these types of cancer in the general population is 10:1. [1] Meanwhile, primary skin lymphomas constitute a relatively rare occurrence among malignant neoplasms of the skin.
Primary skin lymphomas are a heterogeneous group of nonHodgkin lymphomas, mainly derived from mature T-cells and Blymphocytes (65% and 25% of primary skin lymphomas, respectively). [2] Other cancers of the skin are lymphomas derived from natural cytotoxic cells. [2] Skin tumors with at least 6 months of diagnosis and development are limited to the dermal layers and are not derived from systemic lymphomas recognized as primary Editor: N/A.
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skin lymphomas. According to the 2008 WHO-EORTC classification, primary cutaneous anaplastic large-cell lymphoma (C-ALCL) [3] is classified as primary skin lymphoma and constitutes about 10% of all skin lymphoma cases. [4] Initially, C-ALCL, lymphomatoid papulosis (LyP), and borderline variants (where precise differentiation between C-ALCL and LyP is not possible) belong to a group of primary Tcell lymphoproliferative diseases, wherein C-ALCL represents 30% of all primary cutaneous T-cell lymphomas. [3, 5] Histopathologically, C-ALCL is characterized by loss of expression of one or more T-cell antigens (i.e., CD2, CD3, and CD5), high expression of CD30+ antigen, and usually absence of ALK-and EMA antigens. [2, 3, 6] CD30+ antigen expression in >75% of infiltration cells is a condition for C-ALCL diagnosis. [7] This type of lymphoma occurs mainly in adults and males, after the age of 60 years. C-ALCL cases in children have also been described. [8, 9] Clinically, C-ALCL is most prevalent on the skin of the face, trunk, buttocks, or limbs, in the form of single or multiple platelets or ulcerations of 1 to 10 cm in diameter, with reddish or violet color. [3, 6, 10, 11] Establishing a proper diagnosis of C-ALCL is difficult and is often belated because of its nonspecific clinical picture, suggesting other disease entities related to primary or secondary CD30+. [7] This article aimed to describe a case of C-ALCL in the right parotideomasseteric region, considering the rarity of this location and difficulties in the diagnostic process.
Case report
A 73-year-old man was admitted to the Clinic of CranioMaxillofacial and Oral Surgery and Implantology, Medical University of Warsaw, because of a skin tumor in the right parotideomasseteric region. According to medical history, the skin of the right parotideomasseteric region had shown a welldefined skin redness of 10 Â 15 mm, 6 months earlier. His general health condition was good. The patient was seen by a dermatologist who performed the biopsy of the lesion and ordered blood tests. High levels of antimitochondrial and antinuclear antibodies were found in the serum. Immunofluorescence of the collected tissue revealed the presence of IgG and IgM deposits on the cutaneous epidermis, which led to the diagnosis of discoid lupus erythematosus and prescription of Arechin, 250 mg orally, twice a day. Four months after the onset of treatment, significant disease progression and dynamic tumor growth were observed; thus, the patient was referred to the Lymphoid Tumours Clinic of the Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology in Warsaw.
On admission, a well-demarcated exophytic skin tumor with irregular surface without ulceration, measuring 50 Â 70 mm ( Fig. 1) , was observed in the right parotideomasseteric region. The patient reported no pain related to the tumor or impaired sensation on the skin of the face. There was no evidence of facial nerve palsy. Local anesthesia was induced for a histopathological examination that later indicated the presence of pilomatrix carcinoma (trichilemmal carcinoma) in the tumor specimen. Owing to the discrepancy between clinical features (appearance of the lesion and dynamics of the disease) and histopathological examination results, the biopsy material was submitted to another facility, wherein microscopic imaging clearly indicated the presence of anaplastic large cells in the dermis and subcutaneous tissue, characterized by the following immunohistochemistry: LCA+, CD30+, ALK-, CD3+ (weak membrane reaction), CD5-, CKAE1/3, MELAN A-, S100-, and Ki67+++ in about 90% of cells.
To rule out systemic anaplastic large-cell lymphoma, which involves locations other than the skin, trepanobiopsy of bone marrow was performed, and the image indicated no lymphoma infiltration. Diagnosis of potential lymphoma infiltration was further performed with computed tomography (CT) scans of the chest, abdominal cavity, and neck and detailed assessment of the nasopharynx (Fig. 2) . CT confirmed the absence of lymphoma Fig. 3A and B) , and 1 year after the first cycle of chemotherapy, complete remission was achieved. At 5 years after the end of treatment, no recurrent lymphoma was evident ( Fig. 4A and B) .
Discussion
Pilomatrix carcinoma of the parotideomasseteric region is a rare, malignant cancer of the hair follicles, with only few cases reported in the literature. [12] In this study, the first results of histopathological examination indicating pilomatrix carcinoma did not appear to be clinically viable because of the clinical course of the disease and rarity in the skin.
In both C-ALCL and LyP, the expression of CD30+ antigen is a marker. Histologically, the difference between these 2 types of tumors is primarily based on medical history and in-depth clinical examination. [11, 13] In adults, C-ALCL should also be distinguished from atopic dermatitis, gangrene, scleroderma, skin cancer, and other proliferative diseases. [13] In juvenile patients, C-ALCL should be differentiated from rhabdomyosarcoma. [14] The diagnostic criteria for C-ALCL [5] include the expression of CD30+ antigen in >75% of infiltration cells; lack of clinical evidence of LyP, mycosis fungoides, or other cutaneous lymphomas; and no confirmed lymphoma in locations other than the skin layers.
To rule out systemic anaplastic large-cell lymphoma, it is advisable to perform CT scans of the chest, abdominal cavity, and neck in search for different localizations of the disease. [13] In this study, the definitive test was a histopathological examination with an immunohistochemical evaluation of the specimen section. Immunohistochemistry is needed to determine the subtype of skin lymphoma and to differentiate between primary and secondary disease. [4] C-ALCL occurs mainly in males after the age of 60 years, particularly on the skin of the face, trunk, buttocks, or limbs. The age, clinical symptoms, and localization of the disease described in this study were consistent with the general description of C-ALCL. If the tumor affects the limbs, the prognosis is worse. [15] The literature also describes isolated cases of this disease in children. [8, 9, 11] Depending on tumor size, tumor location, and the current course of the disease, several treatment regimens may be considered. Isolated small tumors can be excised or treated with 30 to 46 Gy (2 Gy/fraction) of radiotherapy with a 2 to 3 cm margin around the tumor.
[2] Jepsen et al [11] obtained good results for C-ALCL at 16 to 20 Gy and photon energy of 40 to 50 kV. In about 10% of cases, C-ALCL can spread and affect regional lymph nodes or other organs. In such cases, treatment can involve suitable chemotherapy regimens as in the systemic form. [14] Chemotherapy is also reserved for patients diagnosed with multifocal C-ALCL or those with recurrent disease. [4] Moreover, methotrexate doses of up to 30 mg/week are used in patients with multifocal C-ALCL. [2] Other treatment regimens include the administration of interferon alfa, bexarotene, and anti-CD30 monoclonal antibodies (brentuximab vedotin). [16] In the case described here, because of the course of the disease and the tumor size, chemotherapy was administered using the CHOP scheme, and the patient achieved complete remission after 1 year.
Despite significant cell atypia in C-ALCL histopathology, the prognosis is good. The 10-year survival rate of patients is 90%. [10] Spontaneous or partial tumor remission was observed in 44% of cases. [17] 4. Conclusions C-ALCL is a diagnostic challenge for both clinicians and histopathologists. Establishing a proper diagnosis is possible based on thorough medical history, clinical and imaging examinations, and histopathological evaluation of the biopsy sample from the lesion site. Misdiagnosis can lead to inappropriate therapy and result in disease progression or unnecessary harm to the patient.
